Glioblastoma: pathology, molecular mechanisms and markers
K Aldape, G Zadeh, S Mansouri, G Reifenberger… - Acta …, 2015 - Springer
Recent advances in genomic technology have led to a better understanding of key
molecular alterations that underlie glioblastoma (GBM). The current WHO-based …
molecular alterations that underlie glioblastoma (GBM). The current WHO-based …
The 2016 WHO classification of tumours of the central nervous system: the major points of revision
T Komori - Neurologia medico-chirurgica, 2017 - jstage.jst.go.jp
The updated 2016 edition of the World Health Organization (WHO) Classification of Tumours
of the Central Nervous System (CNS) uses molecular parameters and the histology to define …
of the Central Nervous System (CNS) uses molecular parameters and the histology to define …
Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term results of RTOG 9402
G Cairncross, M Wang, E Shaw, R Jenkins… - Journal of clinical …, 2013 - ascopubs.org
Purpose Anaplastic oligodendrogliomas, pure (AO) and mixed (anaplastic oligoastrocytoma
[AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live …
[AOA]), are chemosensitive, especially if codeleted for 1p/19q, but whether patients live …
Genetics of adult glioma
MKL Goodenberger, RB Jenkins - Cancer genetics, 2012 - Elsevier
Gliomas make up approximately 30% of all brain and central nervous system tumors and
80% of all malignant brain tumors. Despite the frequency of gliomas, the etiology of these …
80% of all malignant brain tumors. Despite the frequency of gliomas, the etiology of these …
ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for …
Diffuse gliomas are represented in the 2007 WHO classification as astrocytomas,
oligoastrocytomas and oligodendrogliomas of grades II and III and glioblastomas WHO …
oligoastrocytomas and oligodendrogliomas of grades II and III and glioblastomas WHO …
IDH1 and IDH2 Mutations in Gliomas
Background A recent genomewide mutational analysis of glioblastomas (World Health
Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate …
Organization [WHO] grade IV glioma) revealed somatic mutations of the isocitrate …
IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II–III diffuse gliomas
A Olar, KM Wani, KD Alfaro-Munoz, LE Heathcock… - Acta …, 2015 - Springer
Diffuse gliomas are up till now graded based upon morphology. Recent findings indicate
that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of …
that isocitrate dehydrogenase (IDH) mutation status defines biologically distinct groups of …
Benefit From Procarbazine, Lomustine, and Vincristine in Oligodendroglial Tumors Is Associated With Mutation of IDH
JG Cairncross, M Wang, RB Jenkins… - Journal of clinical …, 2014 - ascopubs.org
Purpose Patients with 1p/19q codeleted anaplastic oligodendroglial tumors who participated
in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after …
in RTOG (Radiation Therapy Oncology Group) 9402 lived much longer after …
[HTML][HTML] Molecular pathology of tumors of the central nervous system
BW Kristensen, LP Priesterbach-Ackley, JK Petersen… - Annals of oncology, 2019 - Elsevier
Since the update of the 4th edition of the WHO Classification of Central Nervous System
(CNS) Tumors published in 2016, particular molecular characteristics are part of the …
(CNS) Tumors published in 2016, particular molecular characteristics are part of the …
Targeting brain cancer: advances in the molecular pathology of malignant glioma and medulloblastoma
JT Huse, EC Holland - Nature reviews cancer, 2010 - nature.com
Malignant brain tumours continue to be the cause of a disproportionate level of morbidity
and mortality across a wide range of individuals. The most common variants in the adult and …
and mortality across a wide range of individuals. The most common variants in the adult and …